This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (61)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Barron C. Fishburne, MD; David J. Wilson, MD; James T. Rosenbaum, MD; Edward A. Neuwelt, MD

Arch Ophthalmol. 1997;115(9):1152-1156.

Abstract
Objective
To develop a protocol for the treatment of intraocular lymphoma by the intravitreal injection of methotrexate.

Methods
Patients whose results were negative for human immunodeficiency virus and who had pathologically confirmed intraocular lymphoma were eligible for participation in the study. A dose of 400 pg of methotrexate was given intravitreally twice weekly until the vitreous was clinically cleared of cells. Weekly injections were then given for 1 month, followed by monthly injections for 1 year.

Results
Seven eyes of 4 patients were treated. Three patients have completed the protocol. To date, only 1 eye has suffered a significant loss of vision. No serious ocular toxic reaction has been identified.

Conclusions
Survival rates and time to relapse for patients with primary central nervous system lymphoma have improved. The role of ocular radiation therapy must be weighed against the potential drawbacks. Injecting chemotherapeutic agents into the vitreous is worthy of consideration. Four patients treated to date at our institution have had promising results. Intravitreal chemotherapy may result in improved treatment of intraocular lymphoma with reduced morbidity.

Author Affiliations
From the Department of Ophthalmology, Casey Eye Institute (Drs Fishburne, Wilson, and Rosenbaum), and the Department of Medicine (Dr Rosenbaum) and the Division of Neurology (Dr Neuwelt), Oregon Health Sciences University, Portland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience
Frenkel et al.
Br J Ophthalmol 2008;92:383-388.
ABSTRACT | FULL TEXT  

Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption
Vicuna-Kojchen et al.
Br J Ophthalmol 2008;92:231-235.
ABSTRACT | FULL TEXT  

Methotrexate reduces the complications of endophthalmitis resulting from intravitreal injection compared with dexamethasone in a rabbit model.
Deng et al.
IOVS 2006;47:1516-1521.
ABSTRACT | FULL TEXT  

Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma
Jahnke et al.
Ann Oncol 2005;16:1974-1978.
ABSTRACT | FULL TEXT  

Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002
Ferreri et al.
JCO 2003;21:2407-2414.
ABSTRACT | FULL TEXT  

Relevance of intraocular involvement in the management of primary central nervous system lymphomas
Ferreri et al.
Ann Oncol 2002;13:531-538.
ABSTRACT | FULL TEXT  

Bilateral Iridociliary T-Cell Lymphoma
Yahalom et al.
Arch Ophthalmol 2002;120:204-207.
FULL TEXT  

Pharmacokinetics and Toxicity of Intravitreal Chemotherapy for Primary Intraocular Lymphoma
Velez et al.
Arch Ophthalmol 2001;119:1518-1524.
ABSTRACT | FULL TEXT  

Treatment for Primary CNS Lymphoma: The Next Step
Abrey et al.
JCO 2000;18:3144-3150.
ABSTRACT | FULL TEXT  

Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma
de Smet et al.
Br J Ophthalmol 1999;83:448-451.
ABSTRACT | FULL TEXT